Evidence map›Paper›PMID 40284546›Full record

ReviewMicroorganisms2025

Employing Copper-Based Nanomaterials to Combat Multi-Drug-Resistant Bacteria.

Yujie Zhai, Zhuxiao Liang, Xijun Liu, Weiqing Zhang

Abstract readReview
In one paragraph

Review in Microorganisms, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Yujie ZhaiState Key Laboratory of Featured Metal Materials and Life-Cycle Safety for Composite Structures, School of Resources, Environment and Materials, Guangxi University, Nanning 530004, China.
Zhuxiao LiangDepartment of Research, Guangxi Medical University Cancer Hospital, Nanning 530021, China.
Xijun LiuState Key Laboratory of Featured Metal Materials and Life-Cycle Safety for Composite Structures, School of Resources, Environment and Materials, Guangxi University, Nanning 530004, China.ORCID 0000-0002-2624-6901
Weiqing ZhangDepartment of Research, Guangxi Medical University Cancer Hospital, Nanning 530021, China.

Funding

Guangxi Natural Science Fund for Distinguished Young Scholars 2024GXNSFFA010008the National Natural Science Foundation of China 22469002
6 · The paper itself

Abstract

The rise of multi-drug-resistant (MDR) bacteria poses a severe global threat to public health, necessitating the development of innovative therapeutic strategies to overcome these challenges. Copper-based nanomaterials have emerged as promising agents due to their intrinsic antibacterial properties, cost-effectiveness, and adaptability for multifunctional therapeutic approaches. These materials exhibit exceptional potential in advanced antibacterial therapies, including chemodynamic therapy (CDT), photothermal therapy (PTT), and photodynamic therapy (PDT). Their unique physicochemical properties, such as controlled ion release, reactive oxygen species (ROS) generation, and tunable catalytic activity, enable them to target MDR bacteria effectively while minimizing off-target effects. This paper systematically reviews the mechanisms through which Cu-based nanomaterials enhance antibacterial efficiency and emphasizes their specific performance in the antibacterial field. Key factors influencing their antibacterial properties-such as electronic interactions, photothermal characteristics, size effects, ligand effects, single-atom doping, and geometric configurations-are analyzed in depth. By uncovering the potential of copper-based nanomaterials, this work aims to inspire innovative approaches that improve patient outcomes, reduce the burden of bacterial infections, and enhance global public health initiatives.

Indexed as

antibacterial mechanismCu-based nanomaterialsdrug-resistant bacteria

Identifiers

PMID40284546
PMCPMC12029963

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.